

Update on AngelMed Guardian implants in Singapore

Key Highlights:

- All four Singapore patients' AngelMed Guardian alarms are programmed and turned on; and
- Scientific Webinar of the AngelMed Guardian presented to cardiac specialists.

Hydrix Limited (ASX: HYD, '**Hydrix**' or the '**Company**') is pleased to provide the following update regarding the four patient implants of the **AngelMed Guardian** in Singapore announced on 17 August 2020.

AngelMed Guardian device Alarms are now programmed and turned on

All four patients post-operative implant procedures have been completed. Each patient implanted device (IMD) gathered ECG data over the past two-weeks to establish the patient's baseline heart signal. Hydrix Medical and Angel Medical Systems field clinical engineers configured each IMD alarm to each patient's individual physiology. The IMD is fully functioning and thresholds set to recognise changes to the patient's physiology indicative of a heart attack. With this simple post-operative procedure complete, these patients are now benefitting from the device.

In commenting on the latest milestone, Paul Kelly, General Manager – Hydrix Medical said: *"We are very pleased by the success of the four implants in Singapore by Dr Lam which lays the foundation for future growth. An estimated 500,000 people annually suffer from an acute coronary syndrome event of which many may benefit from the AngelMed Guardian."*

Scientific Webinar

Hydrix Medical and Angel Medical Systems presented a scientific webinar to cardiac specialists. Keynote presenters included AngelMed's Founder and key opinion leaders from Harvard Medical School, the Mayo Clinic, Duke University School of Medicine, together with the implanting cardiologist. The webinar presented exclusive insights into the 'how' and 'why' of the AngelMed Guardian system, the profile of high risk patients for which the device is indicated for use, and medical learnings and insights based on the implants performed by Dr Leslie Lam in Singapore.

Recordings of this event are being made available to cardiac industry professionals who are keen to learn more about the AngelMed Guardian system.

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

-ENDS-

Authorisation: This announcement has been authorised by the Board of Hydrix Limited.

Contact Details: For more information, please contact:

Company Enquiries:

Paul Kelly
Hydrix Medical - General Manager
info@hydrix.com
+61 3 9550 8100

Media Enquiries:

Rod North
Managing Director, Bourse Communications
rod@boursecommunications.com.au
+61 3 9510 8309

About Hydrix Limited

Hydrix Limited (ASX: HYD) is a powerful product innovation company. Hydrix' purpose is to enhance the health, safety, and wellbeing of 1 billion lives. The company leverages its powerful product innovation capability across **Hydrix Services** design and engineering to create products which transform markets; **Hydrix Ventures** to pick winning investments in high potential innovative products; and **Hydrix Medical** to create new product revenue streams bringing cardiovascular technologies to market.